Compare BioNano Genomics Inc (BNGO) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs General Mills, Inc. — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while General Mills, Inc. trades at $36.72 (market cap $19.46B). The key difference: General Mills, Inc. is far larger — about 1474.2× BioNano Genomics Inc's market cap, and General Mills, Inc. pays a 6.69% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | GIS | |
|---|---|---|
Market Cap | $13.20M | $19.46B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $51.27 |
52-Week Low | $1.09 | $32.17 |
Enterprise Value | $15.81M | $32.95B |
Dividend Yield | — | 6.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
General Mills (GIS) trades at $36.60, up 1.05% with a bullish technical signal. The stock shows mixed earnings performance with recent Q2 2026 beating estimates, but faces declining revenue and negative net income margin. Analyst consensus is predominantly hold with a $36.14 price target. Cash flow trends show modest improvement, though debt levels have risen to 45% of assets. Recent news highlights cost-saving initiatives and innovation focus amid soft consumer demand.
Outlook remains cautious due to sales pressure and margin challenges, but valuation at 9.23 P/E suggests potential value. Key opportunities include $3 billion savings target by 2030 and brand investments. Risks involve persistent demand weakness, private label competition, and high debt burden. Investors should weigh cost-cutting benefits against top-line headwinds for recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
